Pasadena-based Aliva Pharmaceuticals, a firm developing animal systems for predicting human drug profiles, has raised $12.87M in funding, according to a recent regulatory filing by the firm. Source of the new funding was not disclosed. According to the filing, the firm sold Series A-1 and A-2 preferred shares to 11 investors in the round. No details on the funding have been disclosed, however, California Technology Ventures has the firm listed as a portfolio company. More information »